NO20073405L - Farmasoytisk utforming inneholdende en frigjoringshastighetskontrollerende sammensetning - Google Patents

Farmasoytisk utforming inneholdende en frigjoringshastighetskontrollerende sammensetning

Info

Publication number
NO20073405L
NO20073405L NO20073405A NO20073405A NO20073405L NO 20073405 L NO20073405 L NO 20073405L NO 20073405 A NO20073405 A NO 20073405A NO 20073405 A NO20073405 A NO 20073405A NO 20073405 L NO20073405 L NO 20073405L
Authority
NO
Norway
Prior art keywords
release rate
rate controlling
controlling composition
pharmaceutical design
design containing
Prior art date
Application number
NO20073405A
Other languages
English (en)
Inventor
Nazaneen Pourkavoos
James R Ney
Maria T Cruanes
Yunhui Wu
Saurabh A Palkar
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36118082&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20073405(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO20073405L publication Critical patent/NO20073405L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Farmasøytiske utforminger egnet for oral tilførsel i faste doseringsformer, beskrives. Preparatene omfatter en effektiv mengde av et basesalt av en forbindelse med formel (I) og en frigjøringshastighetskontrollerende sammensetning som omfatter et solubiliseringsmiddel, et geldannende middel og et vannløselig fyllstoff, hvori R1, R2, R3 og R4 er definert heri. Utformingene er egnet for anvendelse for inhibering av HIV-integrase, behandling og forebyggelse av HIV-infeksjon, og behandling, forebyggelse og forsinkelse av påbegynnelsen av AIDS.
NO20073405A 2004-12-03 2007-07-02 Farmasoytisk utforming inneholdende en frigjoringshastighetskontrollerende sammensetning NO20073405L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63294404P 2004-12-03 2004-12-03
PCT/US2005/043727 WO2006060711A2 (en) 2004-12-03 2005-12-02 Pharmaceutical formulation of carboxamide hiv integrase inhibitors containing a release rate controlling composition

Publications (1)

Publication Number Publication Date
NO20073405L true NO20073405L (no) 2007-07-02

Family

ID=36118082

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20073405A NO20073405L (no) 2004-12-03 2007-07-02 Farmasoytisk utforming inneholdende en frigjoringshastighetskontrollerende sammensetning

Country Status (16)

Country Link
US (1) US8852632B2 (no)
EP (2) EP1904067B2 (no)
JP (1) JP5228488B2 (no)
KR (1) KR101351059B1 (no)
CN (1) CN101068550B (no)
AU (1) AU2005311652B2 (no)
BR (1) BRPI0518781A2 (no)
CA (1) CA2588445C (no)
ES (1) ES2755273T3 (no)
IL (1) IL183615A (no)
MX (1) MX2007006635A (no)
NO (1) NO20073405L (no)
NZ (1) NZ555120A (no)
RU (1) RU2382648C2 (no)
WO (1) WO2006060711A2 (no)
ZA (1) ZA200703866B (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2588465C (en) * 2004-12-03 2013-10-01 Merck & Co., Inc. Pharmaceutical composition containing an anti-nucleating agent
UA87884C2 (uk) 2004-12-03 2009-08-25 Мерк Энд Ко., Инк. Безводна кристалічна калієва сіль інгібітора віл-інтегрази
KR20070085702A (ko) * 2004-12-03 2007-08-27 머크 앤드 캄파니 인코포레이티드 Ｕｇｔ1ａ1에 의해 대사된 약물의 약력학을 개선시키기위한 아타자나비르의 용도
CA2702317A1 (en) * 2007-07-09 2009-01-15 Concert Pharmaceuticals, Inc. Novel pyrimidinecarboxamide derivatives
RU2602865C2 (ru) 2009-10-26 2016-11-20 Мерк Шарп И Доум Корп. Твердые фармацевтические композиции, содержащие ингибитор интегразы
EP2552915B1 (en) * 2010-04-01 2017-07-19 Critical Outcome Technologies Inc. Compounds for the treatment of hiv
WO2012009446A1 (en) 2010-07-16 2012-01-19 Concert Pharmaceuticals Inc. Novel pyrimidinecarboxamide derivatives
US9968607B2 (en) 2011-04-25 2018-05-15 Hetero Research Foundation Pharmaceutical compositions of raltegravir, methods of preparation and methods of use therof
ES2450944T3 (es) * 2011-06-01 2014-03-25 Ratiopharm Gmbh Composición y comprimido que comprenden raltegravir
US20150224086A1 (en) * 2012-08-23 2015-08-13 Hetero Research Foundation Pharmaceutical Formulations of Rufinamide
US9763934B2 (en) * 2014-03-05 2017-09-19 Professional Compounding Centers Of America Synergistic effect of poloxamer-based composition and itraconazole on fungus and yeast
KR102293907B1 (ko) 2015-06-30 2021-08-26 한미약품 주식회사 이리노테칸 함유 경구용 고형제제 및 그 제조방법
CN108610338A (zh) * 2016-12-12 2018-10-02 天津国际生物医药联合研究院 一种嘧啶酮酰胺类化合物的制备方法
US20210290548A1 (en) * 2018-06-06 2021-09-23 Merck Sharp & Dohme Corp. Formulations of raltegravir

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE970588A1 (en) * 1997-08-01 2000-08-23 Elan Corp Plc Controlled release pharmaceutical compositions containing tiagabine
JP4965784B2 (ja) * 1999-12-03 2012-07-04 ポリケム・ソシエテ・アノニム バイオアベイラビリティの向上した麦角アルカロイドの徐放性医薬組成物の製造法及びその組成物
HU229938B1 (en) * 2001-05-03 2015-01-28 Hoffmann La Roche Pharmaceutical dosage form of amorphous nelfinavir mesylate
US6673369B2 (en) * 2001-08-29 2004-01-06 Ranbaxy Laboratories Limited Controlled release formulation
SE0102887D0 (sv) * 2001-08-29 2001-08-29 Astrazeneca Ab New formulation
CA2463975A1 (en) * 2001-10-26 2003-05-01 Maria Emilia Di Francesco Dihydroxypyrimidine carboxamide inhibitors of hiv integrase
CA2463976C (en) * 2001-10-26 2007-02-13 Benedetta Crescenzi N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase
EP1499391A2 (en) 2002-04-10 2005-01-26 Merck & Co., Inc. Pharmaceutical compositions containing an hiv integrase inhibitor and a nonionic surfactant
AU2003292436B2 (en) * 2002-12-27 2009-07-30 Msd Italia S.R.L. Tetrahydro-4H-pyrido[1,2-A]pyrimidines and related compounds useful as HIV integrase inhibitors
CA2551254A1 (en) * 2003-12-31 2005-07-21 Pfizer Products Inc. Stabilized pharmaceutical solid compositions of low-solubility drugs, poloxamers, and stabilizing polymers
UA87884C2 (uk) * 2004-12-03 2009-08-25 Мерк Энд Ко., Инк. Безводна кристалічна калієва сіль інгібітора віл-інтегрази
KR20070085702A (ko) 2004-12-03 2007-08-27 머크 앤드 캄파니 인코포레이티드 Ｕｇｔ1ａ1에 의해 대사된 약물의 약력학을 개선시키기위한 아타자나비르의 용도
CA2588465C (en) 2004-12-03 2013-10-01 Merck & Co., Inc. Pharmaceutical composition containing an anti-nucleating agent

Also Published As

Publication number Publication date
CA2588445C (en) 2013-06-25
AU2005311652A1 (en) 2006-06-08
JP2008521932A (ja) 2008-06-26
BRPI0518781A2 (pt) 2008-12-09
MX2007006635A (es) 2007-06-19
EP2586444A1 (en) 2013-05-01
CN101068550A (zh) 2007-11-07
JP5228488B2 (ja) 2013-07-03
KR101351059B1 (ko) 2014-02-17
CN101068550B (zh) 2011-03-30
RU2382648C2 (ru) 2010-02-27
AU2005311652B2 (en) 2010-12-02
EP1904067B1 (en) 2013-11-20
ES2755273T3 (es) 2020-04-22
NZ555120A (en) 2009-11-27
IL183615A (en) 2013-01-31
IL183615A0 (en) 2007-10-31
WO2006060711A2 (en) 2006-06-08
ZA200703866B (en) 2008-03-26
CA2588445A1 (en) 2006-06-08
US8852632B2 (en) 2014-10-07
EP1904067B2 (en) 2017-10-11
US20070292504A1 (en) 2007-12-20
KR20070085695A (ko) 2007-08-27
EP1904067A2 (en) 2008-04-02
EP2586444B1 (en) 2019-09-25
RU2007125122A (ru) 2009-01-10
WO2006060711A3 (en) 2006-09-08

Similar Documents

Publication Publication Date Title
NO20073405L (no) Farmasoytisk utforming inneholdende en frigjoringshastighetskontrollerende sammensetning
NO2020026I1 (no) Raltegravir eller et farmasøytisk akseptabelt salt derav, spesielt kaliumsaltet
WO2005086700A3 (en) Hiv integrase inhibitors
UA84266C2 (uk) Дозована лікарська форма у вигляді таблетки або пелети для перорального введення, яка містить інгібітор pde 4 та полівінілпіролідон, способи її одержання та застосування
EP1467970A4 (en) HYDROXYNAPHTHYRIDINONCARBOXYL ACID AMIDES SUFFICIENT AS INHIBITORS OF THE HIV INTEGRASE
DK1441734T3 (da) Dihydroxypyrimidin-carboxamid-inhibitorer a HIV-integrase
WO2004024078A3 (en) Dihydroxypyridopyrazine-1,6-dione compounds useful as hiv integrase inhibitors
WO2005110414A3 (en) Hiv integrase inhibitors
SG147450A1 (en) Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
WO2007050510A3 (en) Hiv integrase inhibitors
DE60323743D1 (en) N-(substituierte benzyl)-8-hydroxy-1,6-naphthyridin-7- carbonsäureamide als hiv-integrase-hemmer
MXPA05013050A (es) Derivados de bencimidazol, composiciones que los contienen preparacion de los mismos y usos de los mismos.
EP1539714A4 (en) 8-HYDROXY-1-OXO-TETRAHYDROPYRROLOPYRAZINE COMPOUNDS AS INHIBITORS OF HIV INTEGRASE
TW200626567A (en) Benzoxazine and quinoxaline derivatives and uses
TW200640460A (en) HIV integrase inhibitors

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application